-- Company presentation scheduled for August 14, 2018 at 8:00 a.m. EDT --
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company
discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative
infections, today announced that the Company will present a corporate overview at the 2018 Wedbush PacGrow Healthcare Conference
taking place August 14 to 15, 2018 in New York City. Achaogen management will present at 8:00 a.m. Eastern Time on Tuesday, August
14th, 2018.
A live audio webcast of the presentation will be available in the "Investors" section of Achaogen’s website, www.achaogen.com. A replay of the presentation will be archived for 30 days following the
conference for those unable to listen live.
About Achaogen
Achaogen is a biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative
antibacterial treatments for MDR gram-negative infections. Achaogen's first commercial product is ZEMDRI, for the treatment of
adults with complicated urinary tract infections (cUTI), including pyelonephritis. The Achaogen ZEMDRI program was funded in part
with federal funds from the Biomedical Advanced Research and Development Authority (BARDA). The Company is currently developing
C-Scape, an orally-administered beta-lactam/beta-lactamase inhibitor combination, which is also supported by BARDA. Achaogen is
also developing a new aminoglycoside program, which is supported by CARB-X. All product candidates are investigational, have not
been determined to be safe or efficacious, and have not been approved for commercialization. For more information, visit the
Achaogen website at www.achaogen.com.
Investor Contact:
Ashley R. Robinson
LifeSci Partners, LLC
arr@lifesciadvisors.com
Media Contact:
Denise T. Powell
Red House Consulting, LLC
dpowell@achaogen.com
